Federal Register / Vol. 62, No. 244 / Friday, December 19, 1997 / Notices 66667

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated June 9, 1997, and

published in the Federal Register on

June 17, 1997, (62 FR 32824), Dupont

Pharmaceutical Company, 1000 Stewart

Avenue, Garden City, New York 11530,

made application by renewal to the

Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Oxycodone (9143) ............................. II

Hydrocodone (9193) .......................... II

Oxymorphone (9652) ........................ II

The firm plans to manufacture the

listed controlled substances to make

finished products.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Dupont Pharmaceutical

Company to manufacture the listed

controlled substances is consistent with

the public interest at this time.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: November 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–33117 Filed 12–18–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on September 22,

1997, High Standard Products, 1100 W.

Florence Avenue, #B, Inglewood,

California 90301, made application by

renewal to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Methaqualone (2565) ........................ I

Lysergic acid diethylamide (7315) .... I

Tetrahydrocannabinols (7370) .......... I

3,4-Methylenedioxyamphetamine

(7400) ............................................. I

3,4-Methylenedioxy-Nethylamphetamine (7404) .............. I

3,4-Methylenedioxymethamphetamine (7405) .................................. I

4-Methoxyamphetamine (7411) ........ I

Heroin (9200) .................................... I

3-Methylfentanyl (9813) ..................... I

Amphetamine (1100) ......................... II

Methamphetamine (1105) ................. II

Secobarbital (2315) ........................... II

Phencyclidine (7471) ......................... II

Cocaine (9041) .................................. II

Codeine (9050) .................................. II

Hydromorphone (9150) ..................... II

Diphenoxylate (9170) ........................ II

Hydrocodone (9193) .......................... II

Methadone (9250) ............................. II

Morphine (9300) ................................ II

Fentanyl (9801) ................................. II

The firm plans to manufacture

analytical reference standards.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than February

17, 1998.

Dated: November 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–33118 Filed 12–18–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on October 30, 1997,

Ansys Diagnostics, Inc., 2 Goodyear,

Irvine, California 92718, made

application by renewal to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Phencyclidine (7471) ......................... II

1-Piperidinocyclohexanecarbonitrile

(PCC) (8603) ................................. II

Benzoylecgonine (9180) .................... II

The firm plans to manufacture the

listed controlled substances to produce

standards and controls for in-vitro

diagnostic drug testing systems.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than February

17, 1998.

Dated: December 3, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–33114 Filed 12–18–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Bureau of International Labor Affairs;

U.S. National Administrative Office;

National Advisory Committee for the

North American Agreement on Labor

Cooperation; Notice of Open Meeting

by Teleconference

AGENCY: Office of the Secretary, Labor.

ACTION: Notice of open meeting by

teleconference, January 22, 1998.

SUMMARY: Pursuant to the Federal

Advisory Committee Act (Pub. L. 94–

463), the U.S. National Administration

Office (NAO) gives notice of a meeting

of the National Advisory Committee for

the North American Agreement on

Labor Cooperation (NAALC), which was

established by the Secretary of Labor.

The Committee was established to

provide advice to the U.S. Department

of Labor on matters pertaining to the

implementation and further elaboration

of the NAALC, the labor side accord to

the North American Free Trade

Agreement (NAFTA). The Committee is

authorized under Article 17 of the

NAALC.

The Committee consists of 12

independent representatives drawn

from among labor organizations,